Genmab A/S (GMAB:NASDAQ) closed at $50.93 on November 13, 2026, down 1.57% on the day. The stock trades 15.1% below its 52-week high of $59.97 and 115.6% above its 52-week low of $23.62. Over the past year, it gained 71.1%. Genmab A/S is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 12, 2025, GMAB closed higher on 130 days (52%). Its best day was October 28, 2026 (+28.25%) and its worst was March 3, 2026 (-6.71%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 2 times.
Genmab is a cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and its promising first-in-class multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
Find more stocks like GMAB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.